Apr. 8 at 4:17 PM
$SLS Big Pharma is in a
$172B M&A panic, and
$SLS is the atomic bomb they’re all ignoring. 💣🔥
When a company like Eli Lilly or Novartis (sitting on
$53 billion war chest) looks at an asset that can generate
$300B, paying a
$30 billion premium today is actually a bargain.
We're talkin about a valuation correction that could send
$SLS into the triple digits overnight.
$11B $61
$30B $167
$60B $334 🚀💣💥
According to BioSpace, the "floor" for one-off assets is now
$6B–
$11B.
$MRK and
$ABBV are staring at patent cliffs for
$30B/year blockbusters—that’s
$300 BILLION over a decade.
The weekend drop for AACR 2026 shows:
✅ SLS009: it’s crushing the ASXL1 mutation in AML. 🧬💥—the "unbeatable" boss of cancer mutations
✅ GPS Phase 3: Final countdown (72/80 events). Overwhelming efficacy halt could hit ANY time.
At these rock-bottom levels, Big Pharma isn't just buying; they’re stealing. It’s a gift to the little guy to load up before the
$30B+ buyout check hits. 💅🚀
